Evaluation of clinical efficacy of Chemotherapy for Rhabdomyosarcoma in children

Objective: To investigate the clinical characteristics and treatment methods of rhabdomyosarcoma in children and the efficacy of the methods. Methods: The clinical data of 30 children with rhabdomyosarcoma who were admitted to our hospital from August 2013 to August 2017 were retrospectively analyzed. The clinical characteristics were summarized, and the curative effect and prognosis were evaluated. Results: Among all the children (N=30), there were 20 males and 10 females, with a median age of 3.5 years. As to the primary site, there were 13 cases of head and neck, 11 cases of trunk, three cases of urogenital system and three cases of limbs. There were 25 cases of embryonic type, 4 cases of alveolar type and one case of polymorphic type. As regards clinical stage, there were one case of stage I, 9 cases of stage II, 13 cases of stage III and 7 cases of stage IV. There were one case of low risk, 19 cases of medium risk and 10 cases of high risk. Eight cases received surgery alone, 22 cases received combined treatment of surgery and chemotherapy (the chemotherapeutics followed three schemes, low-risk group (VAC+VA), moderate risk group (VAC) and high risk group (alternating use of VDC and IE). Among all the cases (N=30), there were 14 cases of complete remission (CR), five cases of partial remission (PR), four cases of stable disease (SD), and 7 cases of progressive disease (PD). The CR rate was (N=14, 46.7%). The three-year overall survival (OS) rate was (N=19, 63.3%). The clinical efficacy and prognosis of children receiving surgery and chemotherapy were better than those of children receiving surgery alone, and the difference was statistically significant (P<0.05). Conclusion: Rhabdomyosarcoma in children frequently happens in the head, neck and trunk. Embryonic type is the main pathological type of rhabdomyosarcoma. Comprehensive and standardized treatment based on surgery and chemotherapy is an important way to improve the curative effect in the treatment of rhabdomyosarcoma in children.

[1]  Narasimhan P. Agaram,et al.  Expanding the Spectrum of Intraosseous Rhabdomyosarcoma: Correlation Between 2 Distinct Gene Fusions and Phenotype , 2019, The American journal of surgical pathology.

[2]  S. Kuo,et al.  Prognostic Factors and Treatment Outcomes of Adult Patients With Rhabdomyosarcoma After Multimodality Treatment , 2019, AntiCancer Research.

[3]  Z. Bayramoğlu,et al.  Primary Rhabdomyosarcoma of the Breast: Imaging Findings and Literature Review , 2018, Breast Care.

[4]  H. Shirato,et al.  Preliminary results of proton radiotherapy for pediatric rhabdomyosarcoma: a multi‐institutional study in Japan , 2018, Cancer medicine.

[5]  A. Ferrari,et al.  Long‐term results in children with head and neck rhabdomyosarcoma: A report from the Italian Soft Tissue Sarcoma Committee , 2018, Pediatric blood & cancer.

[6]  J. H. van der Lee,et al.  Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study , 2018, Cancer.

[7]  N. Cost,et al.  Current Treatment of Pediatric Bladder and Prostate Rhabdomyosarcoma , 2018, Current Urology Reports.

[8]  S. Wolden,et al.  Rhabdomyosarcoma of the Head and Neck: A Multimodal Approach , 2018, Journal of Neurological Surgery Part B: Skull Base.

[9]  Taosheng Chen,et al.  HNRNPH1 is required for rhabdomyosarcoma cell growth and survival , 2018, Oncogenesis.

[10]  J. Łuszczki,et al.  Combination of Osthole and Cisplatin Against Rhabdomyosarcoma TE671 Cells Yielded Additive Pharmacologic Interaction by Means of Isobolographic Analysis. , 2018, Anticancer research.

[11]  M. Arnold,et al.  Molecular diagnostics in the management of rhabdomyosarcoma , 2017, Expert review of molecular diagnostics.

[12]  J. Vilanova.  WHO Classification of Soft Tissue Tumors , 2017 .

[13]  M. Jiang,et al.  Clinical features and therapeutic efficacy of childhood rhabdomyosarcoma , 2016 .

[14]  S. Sangkhathat.  Current management of pediatric soft tissue sarcomas. , 2015, World journal of clinical pediatrics.

[15]  H. Xiong,et al.  Clinical characteristics and prognosis of childhood rhabdomyosarcoma: a ten-year retrospective multicenter study. , 2015, International journal of clinical and experimental medicine.

[16]  F. Liu,et al.  Effects of preoperative chemotherapy in children with bladder rhabdomyosarcoma , 2015 .

[17]  A. F. Misir,et al.  Dental management long term follow-up of the post radio-chemotherapy—Rhabdomyosarcoma patient: Report of a case , 2014 .

[18]  C. Fletcher,et al.  WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition , 2014, Pathology.

[19]  M. Beltangady,et al.  Lymphatic metastases with childhood rhabdomyosarcoma. A report from the intergroup rhabdomyosarcoma study , 1987, Cancer.

[20]  S. Messina,et al.  High creatine kinase MB isoenzyme activity associated with a rhabdomyosarcoma. , 1983, Clinical chemistry.